AML cells were treated with compound diluent only (controls) or with the MCL1-inhibitor S63845 (HY-100741, MedChemExpress, Monmouth Junction, NJ, USA), the MDM2-inhibitor NVP-HDM201 (Novartis, Switzerland), and the MEK1/2-inhibitor trametinib (HY-10999A, MedChem Express, Monmouth Junction, NJ, USA). Cell viability was determined using the MTT-based in vitro toxicology assay (SIGMA-ALDRICH, St. Louis, MO, USA). For AML cell lines, four independent assays (biological replicates) with four measurements (technical replicates) per dosage were performed. For hematological patient samples two independent assays with three technical replicates per dosage were performed. Data were analyzed on GraphPad Prism software using Mann–Whitney tests and are depicted as average values with standard deviation on column graphs.
Nvp hdm201
Manufactured by Novartis
Sourced in Switzerland
NVP-HDM201 is a laboratory instrument designed for high-throughput sample preparation and analysis. It is a versatile system that can be used for a variety of applications, including sample extraction, purification, and quantification. The core function of NVP-HDM201 is to automate and streamline the sample handling process, improving efficiency and reproducibility in scientific research and drug discovery.
Automatically generated - may contain errors
Lab products found in correlation
Trametinib, by MedChemExpress (1 mentions)
S63845, by MedChemExpress (1 mentions)
Mtt based in vitro toxicology assay, by Merck Group (1 mentions)
Cytarabine, by Merck Group (1 mentions)
Compusyn software, by ComboSyn (1 mentions)
Idarubicin, by Merck Group (1 mentions)
Nvp cgm097, by Novartis (1 mentions)
2 protocols using nvp hdm201
1
AML Treatment Response Evaluation
2
Evaluating AML Cell Responsiveness
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
AML cells were treated with the MDM2 inhibitors NVP-HDM201, NVP-CGM097, idasanutlin (RG7388), the FLT3 inhibitors midostaurin (PKC412), quizartinib (ACC220), gilteritinib (ASP2215) or with genotoxic compounds Cytarabine and idarubicin in equimolar concentrations. NVP-HDM201 and NVP-CGM097 investigational compounds were supplied by Novartis, Switzerland, whereas RG7833, PKC412, ACC220 and ASP2215 were purchased at MCE (MedChemExpress, Monmouth Junction, NJ, USA). Cytarabine and idarubicin were purchased at Sigma-Aldrich (St. Louis, MO, USA) and SelleckChem (Houston, TX, USA). Cell viability was determined using the MTT-based in vitro toxicology assay (TOX1, Sigma-Aldrich) with four repeat measurements per dosage. Data are depicted as XY graphs with median and interquartile range, as box plots or scatter plots with mean values. Statistical analysis was done on GraphPad Prism (version 7, GraphPad software, LaJolla, CA, USA) in grouped analysis and significance calculated by Mann-Whitney test. Combination indexes were calculated on CompuSyn software (version 1.0; ComboSyn, Inc. Paramus, NJ,USA).
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!